You are trying to visit a website containing information about the ongoing offer to the public of shares in Recipharm AB ("Recipharm"). Due to legal restrictions, the information on this part of Recipharm’s website is not accessible to certain persons. We kindly ask you to review the following information and provide the following confirmation each time you wish to access these websites. Please note that the terms set out below may be altered or updated and therefore it is important that you review them each time you visit this page.
The information contained in this section of Recipharm’s website is not intended for, and must not be accessed by, or distributed or disseminated, directly or indirectly, in whole or in part, to persons resident or physically present in United States, Canada, Australia, Japan, Hong Kong, New Zealand, South Africa, or any other jurisdiction where such action is wholly or partially subject to legal restrictions, or would require additional prospectuses, registration or other measures than those required by Swedish law, and do not constitute any offer regarding subscription rights, paid-up subscribed shares or shares in Recipharm (the “Securities”) to any person in said jurisdictions. Nor may the information on the websites be forwarded or reproduced in such a manner that contravenes such restrictions or gives cause to such requirements.
No subscription rights, paid subscribed shares or shares issued by Recipharm have been registered or will be registered under the Securities Act or securities law in any state or jurisdiction of the United States and may not be offered, subscribed for, exercised, pledged, sold, resold, assigned, delivered or transferred, directly or indirectly, in or to the United States, except in accordance with any applicable exception to, or in a transaction not covered by, the Securities Act registration requirements and in accordance with the securities laws of the relevant state or other jurisdiction in the United States. The securities are offered outside the United States with the support of Regulation S of the Securities Act. No offer will be made to the public in the United States. Any offer of securities in the United States will only be made in accordance with an exception to, or in a transaction not covered by, the registration requirements of the Securities Act to a limited number of existing shareholders who (i) are qualified institutional buyers as defined in Rule 144A in the Securities Act, and (ii) has signed and sent a so-called investor facilitates to Recipharm.
No public offering of Securities is made to any countries within the European Economic Area (“EEA”) other than Sweden. In other member states of the EEA which are encompassed by Regulation (EU) 2017/1129 of the European Parliament (the “Prospectus Regulation”) such offering may be made only under the exemption in the Prospectus Regulation.
To access the information contained in this section of Recipharm’s website, all persons must first ensure that they are not subject to legal restrictions that limit their right to access the information on this part of Recipharm’s website.
I therefore certify that:
- I am resident and physically present outside United States, Canada, Australia, Japan, Hong Kong, New Zealand or South Africa or any other jurisdiction where such action is wholly or partially subject to legal restrictions, or would require additional prospectuses, registration or other measures than those required by Swedish law.
- I am resident and physically present (a) in Sweden or (b) outside Sweden and any jurisdiction mentioned under (1) above and are entitled to access the information on this website without being subject to restrictions in any law or other regulations and without any further action being required by Recipharm.
I have read the information, conditions and restrictions above, and "CONFIRM" that I agree to comply with these.
If you are not able to give these confirmations (as applicable), you should click on "DECLINE" below and we cannot provide you with the information on this part of Recipharm’s website.